Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.

2.

A reflection on the possibility of finding a good surrogate.

Alonso A, Meyvisch P, Van der Elst W, Molenberghs G, Verbeke G.

J Biopharm Stat. 2019;29(3):468-477. doi: 10.1080/10543406.2018.1559854. Epub 2019 Jan 26.

PMID:
30686082
3.

Assessing the predictive value of a binary surrogate for a binary true endpoint based on the minimum probability of a prediction error.

Meyvisch P, Alonso A, Van der Elst W, Molenberghs G.

Pharm Stat. 2019 May;18(3):304-315. doi: 10.1002/pst.1924. Epub 2018 Dec 21.

PMID:
30575256
4.

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.

Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, Vandebosch A, Van der Elst W, Molenberghs G, Alonso A.

PLoS One. 2018 Jul 19;13(7):e0200539. doi: 10.1371/journal.pone.0200539. eCollection 2018.

5.

Diversity of late Neogene Monachinae (Carnivora, Phocidae) from the North Atlantic, with the description of two new species.

Dewaele L, Peredo CM, Meyvisch P, Louwye S.

R Soc Open Sci. 2018 Mar 7;5(3):172437. doi: 10.1098/rsos.172437. eCollection 2018 Mar.

6.

Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Diacon AH, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, Jenkins E, Dannemann B.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1612-1615. doi: 10.1164/rccm.201704-0796LE. No abstract available.

7.

Assessing a surrogate predictive value: a causal inference approach.

Alonso A, Van der Elst W, Meyvisch P.

Stat Med. 2017 Mar 30;36(7):1083-1098. doi: 10.1002/sim.7197. Epub 2016 Dec 13.

PMID:
27966231
8.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

9.

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.

Verloes R, Deleu S, Niemeijer N, Crauwels H, Meyvisch P, Williams P.

HIV Med. 2015 Sep;16(8):477-84. doi: 10.1111/hiv.12247. Epub 2015 May 18.

10.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group.

N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.

11.

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies.

Hoetelmans RM, Dierynck I, Smyej I, Meyvisch P, Jacquemyn B, Marien K, Simmen K, Verloes R.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):299-305. doi: 10.1097/QAI.0000000000000011.

PMID:
24121757
12.

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients.

Stellbrink HJ, Arastéh K, Schürmann D, Stephan C, Dierynck I, Smyej I, Hoetelmans RM, Truyers C, Meyvisch P, Jacquemyn B, Mariën K, Simmen K, Verloes R.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):283-9. doi: 10.1097/QAI.0000000000000003.

PMID:
24121756
13.

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF.

Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6. doi: 10.1128/AAC.06126-11. Epub 2012 Mar 5.

14.

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.

Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, Moreno C, Lenz O, Meyvisch P, Peeters M, Sekar V, Simmen K, Verloes R.

Antivir Ther. 2011;16(7):1021-33. doi: 10.3851/IMP1894.

PMID:
22024518
15.

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R.

Gastroenterology. 2010 Mar;138(3):913-21. doi: 10.1053/j.gastro.2009.10.033. Epub 2009 Oct 21.

PMID:
19852962
16.

The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.

N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427.

17.

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.

Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group.

Neurology. 2008 Feb 19;70(8):607-16. doi: 10.1212/01.wnl.0000297512.18364.40.

PMID:
18285535
18.

Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.

Baulac M, Brodie MJ, Elger CE, Krakow K, Stockis A, Meyvisch P, Falter U.

Epilepsia. 2007 Mar;48(3):589-92. Epub 2007 Feb 22.

19.

Intravenous nitrates for pharmacological stimulation during head-up tilt testing in patients with suspected vasovagal syncope and healthy controls.

Aerts AJ, Dendale P, Daniels C, Meyvisch P, Kaufman L, Strobel G, Block P.

Pacing Clin Electrophysiol. 1999 Nov;22(11):1593-8.

PMID:
10598961
20.

Distortion product oto-acoustic emissions as objective audiometry in a group of children with ventilation tubes.

Gordts F, Naessens B, Meyvisch P, Clement PA.

Scand Audiol. 1999;28(2):97-100.

PMID:
10384897
21.

Microbiology of the middle meatus in children requiring adenotonsillectomy.

Gordts F, Abu Nasser I, Pierard D, Meyvisch P, Clement PA.

J Laryngol Otol. 1999 Jan;113(1):24-7.

PMID:
10341914

Supplemental Content

Loading ...
Support Center